 Fennec has a PDUFA date upcoming on Nov. 27 for its sodium thiosulfate formulation to treat hearing loss in children undergoing platinum-based chemotherapy. The company has been working on bringing Pedmark to market for some time - its NDA was rejected last year by the FDA owing to manufacturing issues. 